These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 35417045)

  • 1. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
    Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
    Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
    Jandova J; Wondrak GT
    J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
    Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
    Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
    Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
    Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
    J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
    Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
    Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
    Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
    Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
    Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
    Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
    Dinter L; Karitzky PC; Schulz A; Wurm AA; Mehnert MC; Sergon M; Tunger A; Lesche M; Wehner R; Müller A; Käubler T; Niessner H; Dahl A; Beissert S; Schmitz M; Meier F; Seliger B; Westphal D
    Int J Cancer; 2024 Mar; 154(6):1057-1072. PubMed ID: 38078628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
    Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
    J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
    Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
    Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.
    Bonfill-Teixidor E; Iurlaro R; Handl C; Wichmann J; Arias A; Cuartas I; Emmenegger J; Romagnani A; Mangano L; Lorber T; Berrera M; Godfried Sie C; Köchl F; Eckmann J; Feddersen R; Kornacker M; Schnetzler G; Cicuendez M; Cordero E; Topczewski TE; Ferres-Pijoan A; González J; Martínez-Ricarte F; Muñoz-Couselo E; Tabernero J; Bischoff JR; Pettazzoni P; Seoane J
    Cancer Res; 2022 Jul; 82(14):2552-2564. PubMed ID: 35584009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
    Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
    Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF Inhibitors in Melanoma Management: When Friends Become Foes.
    Chhabra G; Ahmad N
    J Invest Dermatol; 2022 May; 142(5):1256-1259. PubMed ID: 34872726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAF
    Aldaghi SA; Jalal R
    Chem Res Toxicol; 2019 Apr; 32(4):645-658. PubMed ID: 30829029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
    Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS
    Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
    Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
    Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M-CSF as a therapeutic target in BRAF
    Barceló C; Sisó P; de la Rosa I; Megino-Luque C; Navaridas R; Maiques O; Urdanibia I; Eritja N; Soria X; Potrony M; Calbet-Llopart N; Puig S; Matías-Guiu X; Martí RM; Macià A
    Br J Cancer; 2022 Oct; 127(6):1142-1152. PubMed ID: 35725813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
    Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
    Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RICTOR/mTORC2 downregulation in BRAF
    Ponzone L; Audrito V; Landi C; Moiso E; Levra Levron C; Ferrua S; Savino A; Vitale N; Gasparrini M; Avalle L; Vantaggiato L; Shaba E; Tassone B; Saoncella S; Orso F; Viavattene D; Marina E; Fiorilla I; Burrone G; Abili Y; Altruda F; Bini L; Deaglio S; Defilippi P; Menga A; Poli V; Porporato PE; Provero P; Raffaelli N; Riganti C; Taverna D; Cavallo F; Calautti E
    Mol Cancer; 2024 May; 23(1):105. PubMed ID: 38755661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.